Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811590 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00811590 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 3 participants.
The verdict
NCT00811590, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Pilot study, Open-label, Phase II study of Everolimus. Objective: To determine if Everolimus can diminish large gastrointestinal polyps in patients with Peutz-Jeghers Syndrome. Methodology: Polyp size and number will be compared to baseline by FDG-PET and CT and 12 months after treatment with Everolimus. Since this is a pilot study, the polyps prior to treatment will serve as the controls.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811590
The ClinicalTrials.gov registry entry for NCT00811590 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT00811590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811590 about?
NCT00811590 is a clinical study titled "Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome". Pilot study, Open-label, Phase II study of Everolimus. Objective: To determine if Everolimus can diminish large gastrointestinal polyps in patients with Peutz-Jeghers Syndrome. Methodology: Polyp size and number will be compared to baseline by FDG-PET and CT and 12 months after treatment with Ev...
What is the current status of trial NCT00811590?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2008-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00811590?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT00811590?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.